Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TLR8 | Q9NR97 | 11/20 | 0.41 |
| ▸ | TLR7 | Q9NYK1 | 6/20 | 0.41 |
| ▸ | PDE10A | Q9Y233 | 1/20 | 0.35 |
| ▸ | ESR2 | Q92731 | 3/20 | 0.34 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 2/20 | 0.33 |
| ▸ | SREBF2 | Q12772 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5767486 | 0.85 | TLR8 (0.42) | TLR8TLR7PDE10A | |
| SCHEMBL5765048 | 0.84 | TLR8 (0.41) | TLR8TLR7 | |
| SCHEMBL5765502 | 0.84 | TLR8 (0.41) | TLR8TLR7SREBF2 | |
| SCHEMBL5144794 | 0.84 | TLR8 (0.41) | TLR8TLR7SREBF2MAPT | |
| SCHEMBL5765605 | 0.82 | HPGDS (0.40) | TLR8TLR7PDE10A | |
| SCHEMBL5763743 | 0.81 | TLR8 (0.39) | TLR8TLR7 | |
| SCHEMBL1528024 | 0.80 | TLR8 (0.58) | TLR8TLR7PDE10AMAPTNPSR1 | |
| SCHEMBL2400673 | 0.78 | CYP3A4 (0.43) | TLR8TLR7MAPT | |
| SCHEMBL5531698 | 0.77 | DHFR (0.44) | TLR8TLR7 | |
| SCHEMBL2400680 | 0.77 | MAOB (0.45) | APPMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2018-03-01 | — | — | US | disclosed |
| US-20170088559-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2017-03-30 | — | — | US | disclosed |
| US-9546184-B2 | Alkyloxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2017-01-17 | — | — | US | disclosed |
| US-20150266901-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES CO (US) | 2015-09-24 | — | — | US | disclosed |
| EP-1846419-B1 | Alkoxy-substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES CO (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8026366-B2 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2011-09-27 | — | — | US | disclosed |
| US-20080318998-A1 | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2008-12-25 | — | — | US | disclosed |
| EP-1846419-A2 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2007-10-24 | — | — | EP | disclosed |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | 3M INNOVATIVE PROPERTIES COMPANY | 2007-09-06 | — | — | US | disclosed |
| WO-2006086449-A2 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | COLEY PHARMACEUTICAL GROUP, INC. (US) | 2006-08-17 | — | — | WO | disclosed |
| WO-2006009826-A1 | ARYLOXY AND ARYLALKYLENEOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | 3M INNOVATIVE PROPERTIES COMPANY (US) | 2006-01-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150266901-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885PDE10A 3709/4885 |
| US-20170088559-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885PDE10A 3709/4885 |
| US-20080318998-A1 | Alkyloxy Substituted Thiazoloquinolines and Thiazolonaphthyridines | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885PDE10A 3709/4885 |
| US-20070208052-A1 | Aryloxy and arylalkyleneoxy substituted thiazoloquinolines and thiazolonaphthyridines | IL2, TSLP, IFNG | TLR8 82/4885TLR7 37/4885PDE10A 3027/4885 |
| US-20180057509-A1 | ALKYLOXY SUBSTITUTED THIAZOLOQUINOLINES AND THIAZOLONAPHTHYRIDINES | IL2, IFNG, TSLP | TLR8 97/4885TLR7 36/4885PDE10A 3709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.